Gal-3 has been reported to mediate anti-tumor immune responses by inhibiting CD8+ T cells with LAG-3 and inhibiting the expansion of plasmacytoid dendritic cells (23) (Figure 2). This evidence concerns the gene LGALS3 and neoplasm.